Citi Raises Sinopharm Target Price to HK$20.5, Q3 Net Profit Slightly Beats Expectations, Maintains Buy Rating

Stock News10-27

Citi has released a research report maintaining its "Buy" rating on Sinopharm (01099) and slightly raising its target price from HK$20.4 to HK$20.5.

The bank noted that the company's third-quarter revenue was broadly in line with expectations, while net profit slightly outperformed market consensus, mainly benefiting from effective expense control.

Strict expense control offset part of the impact from continued pressure on revenue and gross profit, reflecting the resilience of the company's performance.

Sinopharm's third-quarter revenue came in at RMB 144.8 billion, roughly flat year-on-year; the gross profit margin narrowed by 4 basis points year-on-year to 6.8%.

The selling expense ratio declined by 11 basis points year-on-year, driving the total operating expense ratio down by 10 basis points to 3.6%; the net profit margin expanded by 5 basis points year-on-year to 1.3%, supporting a 4% year-on-year increase in attributable net profit to RMB 1.91 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment